Twist Bioscience Corp (TWST) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2025 (Q1 of Fiscal Year 2026). Twist Bioscience Corporation is a synthetic biology company utilizing a proprietary silicon-based DNA synthesis platform to manufacture synthetic DNA, RNA, and antibody proteins. The company operates as a single reportable segment and serves customers in therapeutics, diagnostics, industry, academic research, and global supply partners.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $103.7 million | $88.7 million |
| Gross Margin | 52.0% | 48.3% |
| Net Loss | $(30.5) million | $(31.6) million |
| Diluted EPS | $(0.50) | $(0.53) |
| Operating Cash Flow | $(24.8) million | $(21.4) million |
| Cash & Short-Term Investments | $197.9 million | $224.1 million |
| Accumulated Deficit | $(1,350.1) million | $(1,273.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 16.9% year-over-year, driven by a 27.4% increase in "DNA synthesis and protein solutions" and an 8.2% increase in "NGS applications."
- Margin Expansion: Gross margin improved by 370 basis points to 52.0%, attributed to revenue growth and continuous process improvement initiatives.
- Expense Management:
- R&D Expenses: Decreased 20% to $17.1 million, primarily due to the sale of the DNA digital data storage business in the prior fiscal year.
- SG&A Expenses: Increased 24% to $69.7 million, driven by a $7.7 million increase in personnel costs and $5.4 million in outside services as the company scales its commercial organization.
- Operational Volume: The number of genes shipped increased 32.2% to approximately 271,000 genes.
- Accounting Changes: Beginning in Fiscal 2026, the company recast revenue disclosures, combining synthetic biology and biopharma services into "DNA synthesis and protein solutions" and renaming "NGS tools" to "NGS applications."
Guidance, Outlook, and Risks
- Liquidity: The company holds $197.9 million in cash and short-term investments. Management expects these resources to fund operations for at least one year from the filing date.
- Capital Expenditures: The company had $12.9 million in committed capital expenditures as of December 31, 2025, with $10.0 million spent on property and equipment in the quarter.
- Legal Proceedings:
- Securities Class Action: A lawsuit filed in 2022 alleging violations of federal securities laws regarding DNA chip technology and accounting practices remains pending. The court granted in part and denied in part the company's motion to dismiss in September 2025; discovery is ongoing.
- Derivative Actions: Two shareholder derivative suits (Shumacher and Sell) have been consolidated and stayed pending the outcome of the securities class action.
- Forward-Looking Risks: Key risks include the ability to achieve profitability, manage growth, defend intellectual property, comply with international regulations, and the impact of competition and economic conditions.
Investor Verification Checklist
- Profitability Path: Verify the timeline and specific milestones required to transition from an accumulated deficit of $1.35 billion to profitability, given the continued net loss of $30.5 million.
- SG&A Trajectory: Assess the sustainability of the 24% increase in SG&A expenses and its impact on future operating leverage.
- Legal Exposure: Monitor the status of the securities class action and derivative suits for potential settlement costs or reputational impact.
- Cash Burn Rate: Confirm the runway provided by the $197.9 million cash balance against the current operating cash burn of approximately $25 million per quarter.
- Revenue Mix: Analyze the sustainability of the growth in "DNA synthesis and protein solutions" versus "NGS applications" to understand dependency on specific market segments.